This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kadmon Holdings, Inc.
Drug Names(s): Interferon Alfacon-1, CIFN, Consensus Interferon, YM643
Description: Infergen's protein sequence is an amalgam of several related interferon proteins. Infergen is approved for the treatment of hepatitis C infections.
Deal Structure: Amgen licensed its rights to market Infergen in the United States and Canada to InterMune, Inc. in June 2001. In other markets, the drug is licensed to Yamanouchi Pharmaceutical Co., Ltd. Yamanouchi granted rights to Amgen to co-develop and market Infergen in Japan, the People's Republic of China, and Taiwan.
On November 28, 2005, Valeant Pharmaceuticals announced that it signed a definitive agreement to acquire the United States and Canadian rights to Infergen from InterMune. Valeant will pay InterMune $113.5 million in cash upon closing, and subsequent milestone payments of up to approximately $22.5 million. Valeant also will acquire an estimated $6.5 million in inventory from InterMune.
In April 2005, Yamanouchi merged with Fujisawa to form Astellas Pharma.
In December 2007, Valeant Pharmaceuticals divested the United States and Canadian rights to Infergen (interferon alfacon-1) to Three Rivers Pharmaceuticals. Valeant will receive from Three Rivers approximately $70.8...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc. Amgen, Inc. Roche Holding AG
Additional information available to subscribers only: